BioSpace News Archive

First subjects dosed with AKS-452, COVID-19 vaccine candidate in the Netherlands trial Vaccine is shelf-stable for 4 months at 25 degrees Celsius (77° Fahrenheit) 176 volunteers will participate in the clinical trial

Adds to Company’s Portfolio of Patents for Disinfection Technology Addressing Global Challenge of Controlling the Spread of Emerging Pathogens

Vizient, Inc. today announces that Intermountain Healthcare, based in Salt Lake City, Utah, has signed a 10-year membership agreement that will enable a new level of collaboration as the two companies work together to implement a wide range of solutions and services aimed at providing patients access to high-quality care at the most affordable cost.

Quotient Limited, a commercial-stage diagnostics company, announced that the company has been recognized with a 2021 Red Dot Product Design Award for the full MosaiQ™ by Quotient system.

TriNetX announces that Ospedale San Raffaele, Italy’s leading biomedical research institute and the country’s representative in the European University Hospital Alliance, has joined the TriNetX network to increase its commitment to clinical trial research and to build on its growing position as a leader in the field of gene therapy for rare diseases.

Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in manufacturing and selling non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, today announced orders for Q1 2021.

Kineta, Inc., a clinical stage biotechnology company focused on the development of novel immunotherapies in oncology, announced today the presentation of new preclinical data on its VISTA antagonist antibody at the American Association for Cancer Research (AACR) Annual Meeting 2021.

Horizon Therapeutics plc Named One of the Fortune 100 Best Companies to Work For ® - Company also named to the 2021 Best Places to Work in Chicago list by Crain’s Chicago Business -

IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced the appointment of George A. Gauthier to the newly created position of Chief Commercial Officer.

Breakthrough PPMO Technology Delivers High Levels of RNA Therapeutic Throughout the Brain Company Actively Progressing Discovery Activities in Neurodegenerative Diseases and Remains on Track to Nominate a CNS Development Candidate In 2021